Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBC103 in refractory pediatric rheumatic diseases
NCT07184450Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBC103 in juvenile dermatomyositis (JDM), juvenile idiopathic arthritis (JIA) and systemic sclerosis (SSc), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety and Tolerability of CAR-T at 28 days, Total Improvement Score at 6 months and 10 more. Started Sep 2025; status: recruiting.
02
Drugs
PBC103
03
Conditions
juvenile dermatomyositis (JDM)juvenile idiopathic arthritis (JIA)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07184450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184450.